These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 26447961)

  • 1. Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis.
    Qamar AA
    J Clin Gastroenterol; 2015; 49 Suppl 1():S28-32. PubMed ID: 26447961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease.
    Puri P; Sanyal AJ
    Clin Liver Dis; 2018 Feb; 22(1):121-132. PubMed ID: 29128052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gut microbiota and nonalcoholic steatohepatitis].
    Kessoku T; Imajo K; Kobayashi T; Honda Y; Ogawa Y; Yoneda M; Saito S; Nakajima A
    Nihon Yakurigaku Zasshi; 2018; 152(4):187-193. PubMed ID: 30298840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.
    Ferolla SM; Couto CA; Costa-Silva L; Armiliato GN; Pereira CA; Martins FS; Ferrari Mde L; Vilela EG; Torres HO; Cunha AS; Ferrari TC
    Nutrients; 2016 Jun; 8(7):. PubMed ID: 27367724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.
    Federico A; Dallio M; Godos J; Loguercio C; Salomone F
    Transl Res; 2016 Jan; 167(1):116-24. PubMed ID: 26318867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Gut Microbiota and Nonalcoholic Fatty Liver Disease.
    Quigley EM; Monsour HP
    Semin Liver Dis; 2015 Aug; 35(3):262-9. PubMed ID: 26378643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.
    Del Chierico F; Nobili V; Vernocchi P; Russo A; De Stefanis C; Gnani D; Furlanello C; Zandonà A; Paci P; Capuani G; Dallapiccola B; Miccheli A; Alisi A; Putignani L
    Hepatology; 2017 Feb; 65(2):451-464. PubMed ID: 27028797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
    Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
    Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactobacillus paracasei Induces M2-Dominant Kupffer Cell Polarization in a Mouse Model of Nonalcoholic Steatohepatitis.
    Sohn W; Jun DW; Lee KN; Lee HL; Lee OY; Choi HS; Yoon BC
    Dig Dis Sci; 2015 Nov; 60(11):3340-50. PubMed ID: 26143342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota and the liver.
    Federico A; Dallio M; Caprio GG; Ormando VM; Loguercio C
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):385-398. PubMed ID: 28927250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
    Utzeri E; Usai P
    World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut Microbiota and Complications of Liver Disease.
    Acharya C; Bajaj JS
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota-related complications in cirrhosis.
    Gómez-Hurtado I; Such J; Sanz Y; Francés R
    World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.